Investing.com - Stifel has reiterated its Buy rating and $50.00 price target on MBX Biosciences Inc (NASDAQ:MBX), highlighting the company’s aggressive advancement of its obesity drug portfolio with a ...

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 ...

MBX Biosciences Inc stock reached an all-time high of $34.85, marking a significant milestone for the company. This achievement reflects a robust 49.41% increase over the past year, with an even more ...

MBX shares are currently trading at $28.67, with analysts maintaining a Strong Buy consensus and a high target of $80, according to InvestingPro data. The price target increase comes after MBX’s ...

Fintel reports that on December 19, 2025, Stifel maintained coverage of MBX Biosciences (NasdaqGS:MBX) with a Buy recommendation. Analyst Price Forecast Suggests 108.57% Upside As of December 6, 2025, ...

I have covered MBX Biosciences, Inc. (MBX) twice in notes for Seeking Alpha this year, the first time on May 31st, and the second time on September 22nd, both times issuing a Buy recommendation. To ...

Investing.com - Goldman Sachs initiated coverage of MBX Biosciences Inc (NASDAQ:MBX) with a Sell rating and a $18.00 price target, implying 47% downside potential from the current price of $33.94.

In recent months, MBX Biosciences reported positive topline Phase 2 results for its lead drug canvuparatide in hypoparathyroidism and completed an upsized US$200,000,000 capital raise, while ...